Tildrakizumab Shows Efficacy in Plaque Psoriasis

Tildrakizumab was associated with improvements in disease severity in patients with moderate-to-severe plaque psoriasis, according to results from a new study in the Journal of Drugs in Dermatology. 

Researchers for the phase 4, multicenter, uncontrolled, open-label trial enrolled 55 adult patients with moderate-to-severe plaque psoriasis in the study (45 were included in the final analysis). They sought to evaluate the real-world outcomes of tildrakizumab, a humanized anti-interleukin-23 p19 monoclonal antibody, in treating moderate-to-severe plaque psoriasis over a 64-week treatment period. Study patients received tildrakizumab 100 mg at weeks 0 and 4, and every 12 weeks thereafter until week 52. The primary outcome measures of effectiveness were the reduction in body surface area (BSA) affected by psoriasis, the static Physician Global Assessment (sPGA), and the Psoriasis Area and Severity Index (PASI).

The study results showed a significant decrease in mean BSA from 14.5% to 2.1% by week 64 [an 83.1% reduction (P < 0.001)]. sPGA score improved by 67.6% (P < 0.001). The researcher also reported a significant reduction (89.6%, P < 0.001) combined sPGA x BSA score also saw a substantial reduction of 89.6% (P < 0.001). PASI scores also showed improvements at various intervals, with 87.0% of patients achieving at least a 75% improvement by week 52, 56.5% achieving a 90% improvement, and 32.6% achieving complete clearance (P < 0.001).

There were 85 treatment-emergent adverse events reported in 34 patients, none of which were attributed to tildrakizumab. The small sample size was cited as a limitation.

"Tildrakizumab treatment resulted in improvement across multiple measures of disease severity in adult patients with moderate-to-severe plaque psoriasis in the real-world setting," the authors wrote in the conclusion. "The reported AEs were consistent with the previously established safety profile of tildrakizumab."

Source: Heim J, et al. Journal of Drugs in Dermatology. 2024. Doi:10.36849/JDD.8217